ArticleJournal of neuroinflammation2025
Diabetes exacerbates myasthenia gravis by enhancing pathological thymic output via the GPR183-7α,25-OHC axis.
Article in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundDiabetes mellitus (DM) could exacerbate experimental autoimmune myasthenia gravis (EAMG) by affecting both the innate and adaptive immune systems, although the specific mechanism remains unclear. GPR183, a G protein-coupled receptor predominantly expressed on immune cells, contributes to autoimmune disease development by directing immune cell migration to secondary lymphoid organs. However, the correlation between GPR183 and MG has not been reported.
methodsResearchers established a combined DM and EAMG model. Thymic immune cell and cytokine changes were assessed by flow cytometry. Transcriptomic profiles of sorted CD4+CD8− and CD4−CD8+ thymic T cells were analyzed via RNA sequencing. Serum steroid hormones were quantified by LC-MS/MS. The GPR183-7α,25-OHC pathway was evaluated using PCR, immunohistochemistry, and western blotting. In vivo blockade of GPR183 with inhibitor NIBR189 assessed its immune effects in EAMG rats with/without DM.
resultsOur study indicated that EAMG rats with DM exhibited more severe weight loss, thymus atrophy, and immune microenvironment alterations. Specifically, DM increased the percentages of mature and exported CD62L+ T cells in the thymus and peripheral blood of EAMG rats. RNA sequencing revealed that diabetes promotes GPR183 expression on thymic T cells, primarily in the CD62L⁺ T cell subset in EAMG rats. DM activates the GPR183 ligand, elevates serum 7α,25-hydroxycholesterol levels, and enhances hepatic cholesterol metabolism. GPR183 inhibition induces thymic T cell retention by selectively blocking CD62L⁺ T cell migration to the periphery. Moreover, GPR183 inhibitors weaken the adaptive immune function in DM + EAMG rats by expanding Treg cells, inhibiting Tfh/ASC differentiation, and reducing CD62L⁺ B cells.
conclusionDiabetes significantly upregulates thymic GPR183 (especially on CD62L⁺ T cells) and promotes synthesis of its ligand 7α,25-OHC via hepatic cholesterol reprogramming, accelerating thymic T cells egress. This provides a novel therapeutic approach and a new perspective on how metabolic disorders reshape immune cell dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.